Study provides genetic evidence on new osteoporosis drug heart attack risk

New research highlights potential safety concerns around women taking romosozumab, a new anti-osteoporosis drug available on the NHS. The University of Bristol-led study, published in Arthritis & Rheumatology, analysed genetic data on nearly 34,000 people. Despite romosozumab being particularly effective at reducing the risk of fracture in women with severe osteoporosis, potential safety concerns following trial data suggest the drug may […]